Close Menu
Thursday, January 15
Healthcare

FDA clears Insulet’s Omnipod 5 for type 2 diabetes (NASDAQ:PODD)

1 Min Read


(*2*)

(*5*) Stethoscope rests on headlines concerning diabetes

RapidEye

  • Insulet (NASDAQ:PODD) mentioned it has acquired FDA clearance for its Omnipod 5 Automated Insulin Delivery, or AID, system for the therapy of type 2 diabetes in adults.
  • The firm mentioned the clearance makes Omnipod 5 the one AID system accredited for each type 1 and type 2 diabetes administration.



Source: Seekingalpha

Share.

Related Posts